New York Office
Michael is an experienced biopharma executive with over 15 years of industry experience. He has worked in a wide variety of corporate environments including Epizyme, Forest Labs, Eisai and Kastle Therapeutics. Notable transactions include the acquisition and reacquisition of Epizyme’s EZH2 program, revision of Epizyme’s Celgene collaboration, the licensing of BELVIQ from Arena Pharmaceuticals, the licensing of AKYNZEO from Helsinn, and the acquisition of KYNAMRO from Ionis Pharmaceuticals. Michael holds a B.S. in molecular biology from Cornell University, an M.S. from the University of Illinois, and a J.D. from Fordham Law School.